Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.46 |
| ▸ | USP5 | P45974 | 1/20 | 0.44 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11829725 | 0.87 | KDM1A (0.56) | ALDH1A1SMN1; SMN2GRIN2BL3MBTL1KDM1A | |
| SCHEMBL5222314 | 0.85 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2USP5 | |
| SCHEMBL5250524 | 0.82 | KDM4E (0.48) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL22687353 | 0.79 | ITGB3 (0.41) | ALDH1A1 | |
| SCHEMBL75440 | 0.79 | — | — | |
| SCHEMBL5217873 | 0.79 | DRD4 (0.42) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL7277717 | 0.78 | KDM1A (0.44) | ALDH1A1SMN1; SMN2GRIN2BL3MBTL1KDM1A | |
| Hydrochloric Acid SCHEMBL7323838 | 0.78 | KDM1A (0.44) | ALDH1A1SMN1; SMN2GRIN2BL3MBTL1KDM1A | |
| Bicarbonate SCHEMBL7573346 | 0.77 | AKR1C3 (0.63) | ALDH1A1GRIN2BL3MBTL1AKR1C3AKR1C1 | |
| Bicarbonate SCHEMBL10725172 | 0.77 | ITGB3 (0.41) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1399433-B1 | FLUOROPYRROLIDINES AS DIPEPTIDYL PEPTIDASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2007-08-22 | — | — | EP | disclosed |
| US-7183290-B2 | Fluoropyrrolidines as dipeptidyl peptidase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-27 | — | — | US | disclosed |
| US-20040242636-A1 | Enzyme inhibitors as antiinflammatory ageents for psoriasis, obesity | SMITHKLINE BEECHAM CORPORATION | 2004-12-02 | — | — | US | disclosed |
| EP-1399433-A2 | FLUOROPYRROLIDINES AS DIPEPTIDYL PEPTIDASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-03-24 | — | — | EP | disclosed |
| WO-2003002553-A2 | FLUOROPYRROLIDINES AS DIPEPTIDYL PEPTIDASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-01-09 | — | — | WO | disclosed |
| EP-0103927-B1 | CONVERTING ENZYME INHIBITORS | Norwich Eaton Pharmaceuticals, Inc. (US) | 1986-06-04 | — | — | EP | disclosed |
| US-4442038-A | Converting enzyme inhibitors | NORWICH EATON PHARMACEUTICALS, INC. | 1984-04-10 | — | — | US | disclosed |
| US-4442038-A | Converting enzyme inhibitors | NORWICH EATON PHARMACEUTICALS, INC. | 1984-04-10 | — | — | US | disclosed |
| EP-0103927-A1 | Converting enzyme inhibitors | Norwich Eaton Pharmaceuticals, Inc. (US) | 1984-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242636-A1 | Enzyme inhibitors as antiinflammatory ageents for psoriasis, obesity | DPP4, DPP7, DPP3 | ALDH1A1 531/4885SMN1; SMN2 4593/4885GRIN2B 3955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.